IDEAS home Printed from https://ideas.repec.org/a/wly/nuhsci/v21y2019i1p112-118.html
   My bibliography  Save this article

Illness trajectory of initial infection for patients with hepatitis C: A qualitative study

Author

Listed:
  • Shu‐Mei Tsai
  • Jung‐Ta Kao
  • Yun‐Fang Tsai

Abstract

Little is known about how the initial infection and diagnosis of hepatitis C virus (HCV) impacts a patient's experience of living with and adjusting to the disease. In the present qualitative, descriptive study, we explored the initial experiences of patients in Taiwan diagnosed with HCV. Eighteen participants were recruited from hepatology clinics of a teaching hospital in Taichung, Taiwan by purposive sampling. Data were collected via in‐depth face‐to‐face interviews and analyzed by conventional content analysis. The core theme describing the illness trajectory was “Oasis in the desert”. Two main themes described the participants' experiences and adjustment to the diagnosis of hepatitis C: “Getting lost in the journey” and “The calm after the storm”. Our findings highlight the need for health‐care providers to coordinate interactions between patients and multi‐disciplinary teams to manage the integration of different treatment options. There is a demand for educational interventions and online information for patients and the general population, which could improve knowledge of HCV.

Suggested Citation

  • Shu‐Mei Tsai & Jung‐Ta Kao & Yun‐Fang Tsai, 2019. "Illness trajectory of initial infection for patients with hepatitis C: A qualitative study," Nursing & Health Sciences, John Wiley & Sons, vol. 21(1), pages 112-118, March.
  • Handle: RePEc:wly:nuhsci:v:21:y:2019:i:1:p:112-118
    DOI: 10.1111/nhs.12568
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/nhs.12568
    Download Restriction: no

    File URL: https://libkey.io/10.1111/nhs.12568?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Swathi Iyengar & Kiu Tay-Teo & Sabine Vogler & Peter Beyer & Stefan Wiktor & Kees de Joncheere & Suzanne Hill, 2016. "Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis," PLOS Medicine, Public Library of Science, vol. 13(5), pages 1-22, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rakesh Aggarwal & Qiushi Chen & Amit Goel & Nicole Seguy & Razia Pendse & Turgay Ayer & Jagpreet Chhatwal, 2017. "Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-15, May.
    2. Dubois, Pierre & Magnac, Thierry, 2024. "Optimal intertemporal curative drug expenses: The case of hepatitis C in France," Journal of Health Economics, Elsevier, vol. 94(C).
    3. Salas-Vega, Sebastian & Shearer, Emily & Mossialos, Elias, 2020. "Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US," Social Science & Medicine, Elsevier, vol. 258(C).
    4. Aris Angelis & Huseyin Naci & Allan Hackshaw, 2020. "Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies," PharmacoEconomics, Springer, vol. 38(12), pages 1297-1308, December.
    5. Joost W. Geenen & Cornelis Boersma & Olaf H. Klungel & Anke M. Hövels, 2019. "Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 857-867, August.
    6. Sabine Vogler, 2019. "Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies," Empirica, Springer;Austrian Institute for Economic Research;Austrian Economic Association, vol. 46(3), pages 443-469, August.
    7. Jae Ho Jung & Dae Jung Kim & Kangho Suh & Jaeeun You & Je Ho Lee & Kyung In Joung & Dong Churl Suh, 2021. "International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    8. Sarah Garner & Andrew Rintoul & Suzanne R. Hill, 2018. "Value-Based Pricing: L’Enfant Terrible?," PharmacoEconomics, Springer, vol. 36(1), pages 5-6, January.
    9. David Beheshti, 2019. "Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1449-1461, December.
    10. Roediger, Alexander & Wilsdon, Tim & Haderi, Artes & Pendleton, Kathy & Azais, Boris, 2019. "Competition between on-patent medicines in Europe," Health Policy, Elsevier, vol. 123(7), pages 652-660.
    11. Daniela Moye-Holz & S. Vogler, 2022. "Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 67-77, January.
    12. Salant, Stephen, 2021. "Arbitrage Deterrence: A Theory of International Drug Pricing," RFF Working Paper Series 21-07, Resources for the Future.
    13. Tomasz Zaprutko & Dorota Kopciuch & Krzysztof Kus & Piotr Merks & Monika Nowicka & Izabela Augustyniak & Elżbieta Nowakowska, 2017. "Affordability of medicines in the European Union," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-13, February.
    14. Roy Lothan & Noa Gutman & Dan Yamin, 2022. "Country versus pharmaceutical company interests for hepatitis C treatment," Health Care Management Science, Springer, vol. 25(4), pages 725-749, December.
    15. Chunming Xu & Debao Zhu, 2021. "On Conflicts between Pharmaceutical Patent Protection and the Right to Life and Health Based on a Stackelberg Game," IJERPH, MDPI, vol. 18(3), pages 1-13, January.
    16. Jalal Dahham & Ingrid Kremer & Mickaël Hiligsmann & Kamal Hamdan & Abdallah Nassereddine & Silvia M. A. A. Evers & Rana Rizk, 2023. "Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 31-38, January.
    17. Lauren E. Cipriano & Shan Liu & Kaspar S. Shahzada & Mark Holodniy & Jeremy D. Goldhaber-Fiebert, 2018. "Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes," Medical Decision Making, , vol. 38(7), pages 849-865, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:nuhsci:v:21:y:2019:i:1:p:112-118. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://doi.org/10.1111/(ISSN)1442-2018 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.